

November 05, 2025

BSE Limited

Corporate Relation Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001

Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department Exchange Plaza, C-1, Block - G Bandra-Kurla Complex Bandra (East), Mumbai - 400051

Symbol: MARKSANS

Sub: Press Release

Marksans Pharma Limited's wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its product Exemestane 25mg film-coated tablets.

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited in UK has received Marketing Authorization for its product **Exemestane 25mg film-coated tablets** from UK MHRA.

Please take the above information on record.

Thanking you.

Yours faithfully For **Marksans Pharma Limited**

Harshavardhan Panigrahi Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Ltd.

www.marksanspharma.com